Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial

James W Holcroft, M. J. Vassar, C. J. Weber

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

A 7-day infusion of prostaglandin E1 (PGE1), an immunomodulator, was evaluated in a prospective, randomized, placebo-controlled, double-blinded trial in surgical patients with the adult respiratory distress syndrome (ARDS). The drug seemed to improve pulmonary function - only two PGE1 patients died with severe pulmonary failure compared with nine placebo patients (p = 0.01). Survival at 30 days after the end of the infusion - the predetermined end point of the study - was significantly better in the patients given PGE1 (p = 0.03), with 15 of 21 PGE1 patients (71%) alive at this time compared with seven of 20 placebo patients (35%). Improvement in overall survival in the PGE1 patients did not reach statistical significance (p = 0.08). Overall survival in patients initially free of severe organ failure, however, was significantly better in the PGE1 patients (p = 0.03). Of the six PGE1 patients free of severe organ failure at time of entry, all survived to leave the hospital; of the 10 placebo patients initially free of severe organ failure, four survived. The drug had no serious side effects and did not potentiate susceptibility to infection. PGE1 is a promising agent for the treatment of ARDS.

Original languageEnglish (US)
Pages (from-to)371-378
Number of pages8
JournalAnnals of Surgery
Volume203
Issue number4
StatePublished - 1986

Fingerprint

Alprostadil
Adult Respiratory Distress Syndrome
Survival
Placebos
Lung
Immunologic Factors
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery

Cite this

Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial. / Holcroft, James W; Vassar, M. J.; Weber, C. J.

In: Annals of Surgery, Vol. 203, No. 4, 1986, p. 371-378.

Research output: Contribution to journalArticle

@article{97dfcec1b9d747929657bceb0fe3e667,
title = "Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial",
abstract = "A 7-day infusion of prostaglandin E1 (PGE1), an immunomodulator, was evaluated in a prospective, randomized, placebo-controlled, double-blinded trial in surgical patients with the adult respiratory distress syndrome (ARDS). The drug seemed to improve pulmonary function - only two PGE1 patients died with severe pulmonary failure compared with nine placebo patients (p = 0.01). Survival at 30 days after the end of the infusion - the predetermined end point of the study - was significantly better in the patients given PGE1 (p = 0.03), with 15 of 21 PGE1 patients (71{\%}) alive at this time compared with seven of 20 placebo patients (35{\%}). Improvement in overall survival in the PGE1 patients did not reach statistical significance (p = 0.08). Overall survival in patients initially free of severe organ failure, however, was significantly better in the PGE1 patients (p = 0.03). Of the six PGE1 patients free of severe organ failure at time of entry, all survived to leave the hospital; of the 10 placebo patients initially free of severe organ failure, four survived. The drug had no serious side effects and did not potentiate susceptibility to infection. PGE1 is a promising agent for the treatment of ARDS.",
author = "Holcroft, {James W} and Vassar, {M. J.} and Weber, {C. J.}",
year = "1986",
language = "English (US)",
volume = "203",
pages = "371--378",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial

AU - Holcroft, James W

AU - Vassar, M. J.

AU - Weber, C. J.

PY - 1986

Y1 - 1986

N2 - A 7-day infusion of prostaglandin E1 (PGE1), an immunomodulator, was evaluated in a prospective, randomized, placebo-controlled, double-blinded trial in surgical patients with the adult respiratory distress syndrome (ARDS). The drug seemed to improve pulmonary function - only two PGE1 patients died with severe pulmonary failure compared with nine placebo patients (p = 0.01). Survival at 30 days after the end of the infusion - the predetermined end point of the study - was significantly better in the patients given PGE1 (p = 0.03), with 15 of 21 PGE1 patients (71%) alive at this time compared with seven of 20 placebo patients (35%). Improvement in overall survival in the PGE1 patients did not reach statistical significance (p = 0.08). Overall survival in patients initially free of severe organ failure, however, was significantly better in the PGE1 patients (p = 0.03). Of the six PGE1 patients free of severe organ failure at time of entry, all survived to leave the hospital; of the 10 placebo patients initially free of severe organ failure, four survived. The drug had no serious side effects and did not potentiate susceptibility to infection. PGE1 is a promising agent for the treatment of ARDS.

AB - A 7-day infusion of prostaglandin E1 (PGE1), an immunomodulator, was evaluated in a prospective, randomized, placebo-controlled, double-blinded trial in surgical patients with the adult respiratory distress syndrome (ARDS). The drug seemed to improve pulmonary function - only two PGE1 patients died with severe pulmonary failure compared with nine placebo patients (p = 0.01). Survival at 30 days after the end of the infusion - the predetermined end point of the study - was significantly better in the patients given PGE1 (p = 0.03), with 15 of 21 PGE1 patients (71%) alive at this time compared with seven of 20 placebo patients (35%). Improvement in overall survival in the PGE1 patients did not reach statistical significance (p = 0.08). Overall survival in patients initially free of severe organ failure, however, was significantly better in the PGE1 patients (p = 0.03). Of the six PGE1 patients free of severe organ failure at time of entry, all survived to leave the hospital; of the 10 placebo patients initially free of severe organ failure, four survived. The drug had no serious side effects and did not potentiate susceptibility to infection. PGE1 is a promising agent for the treatment of ARDS.

UR - http://www.scopus.com/inward/record.url?scp=0022558411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022558411&partnerID=8YFLogxK

M3 - Article

VL - 203

SP - 371

EP - 378

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 4

ER -